SEQUENCE LISTING

<110> Applied Research Systems ARS Holding N.V.

<120> NOVEL CXCL8 ANTAGONISTS

<130> WO932

<160> 6

<170> PatentIn version 3.1

<210> 1
<211> 297
<212> DNA
<213> homo sapiens
<220>
<223> Human CXCL8 coding sequence

<400> 1
atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt   60

gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac   120

tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac   180

tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc   240

aaggaaaact gggtgcagag ggttgtggag aagtttttga agagggctga gaattca   297

<210> 2
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<223> Mature human CXCL8

<400> 2

Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
1   5   10   15

Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
                20   25   30

His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
                35   40   45

Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys
        50   55   60

Phe Leu Lys Arg Ala Glu Asn Ser
65   70

```
        <210>   3
        <211>   297
    5   <212>   DNA
        <213>   Synthetic construct
        <220>
        <223>   CXCL8-1B3 coding sequence

   10   <400>   3
        atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt     60

        gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac    120

   15   tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac    180

        tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc    240

        aaggaaaact gggtgcaggc ggttgtggag gcgttttttgg cgagggctga gaattca      297
   20


        <210>   4
        <211>   72
        <212>   PRT
   25   <213>   Synthetic construct
        <220>
        <223>   Mature CXCL8-1B3

        <400>   4
   30
        Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
        1               5                   10                  15


   35   Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
                        20                  25                  30


        His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
   40                   35                  40                  45


        Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Ala Val Val Glu Ala
                50                  55                  60
   45

        Phe Leu Ala Arg Ala Glu Asn Ser
        65                  70

   50
        <210>   5
        <211>   297
        <212>   DNA
        <213>   Synthetic construct
   55   <220>
        <223>   CXCL8-2B3 coding sequence

        <400>   5
```

```
atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt     60

gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac    120

tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac    180

tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc    240

aaggaaaact gggtgcagag ggttgtggag gcgtttttgg cggcggctga gaattca       297
```

```
<210>  6
<211>  72
<212>  PRT
<213>  Synthetic construct
<220>
<223>  Mature CXCL8-2B3

<400>  6
```

```
Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
1               5                   10                  15


Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
            20                  25                  30


His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
        35                  40                  45


Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Ala
        50                  55                  60


Phe Leu Ala Ala Ala Glu Asn Ser
65                  70
```